You have 9 free searches left this month | for more free features.

Condition

Bioequivalence (1)

Invasive Aspergillosis (1)

Primary Visceral Leishmaniasis (1)

Overall Status

Completed (1)

Not yet recruiting (1)

Recruiting (1)

Sign in for free

Phase

phase 1 (1)

phase 2 (1)

phase 3 (1)

Sponsor

CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. (1)

Drugs for Neglected Diseases (1)

F2G Biotech GmbH (1)

Collaborator

Iqvia Pty Ltd (1)

Novartis Pharmaceuticals (1)

Intervention

ambisome® (3)

amphotericin b liposome for injection (1)

lxe408 (1)

olorofim (1)

placebo (1)

Study Documents

Intervention Type

drug (3)

other (1)

Funder Type

Industry (2)

Other (1)

Study Type

Interventional (3)

ambisome®

Showing 1 - 3 of 3

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

LAST UPDATED

Bioequivalence Trial in Wuhan (Amphotericin B liposome for injection, AmBisome®)

Completed

Bioequivalence

Amphotericin B liposome for injection
AmBisome®

Wuhan, Hubei, China

Wuhan Medical Treatment Center

Jul 28, 2021

Invasive Aspergillosis Trial in Pathum Wan (Olorofim, AmBisome®)

Recruiting

Invasive Aspergillosis

Olorofim
AmBisome®

Sacramento, California
+44 more

Dec 16, 2022

Primary Visceral Leishmaniasis Trial (LXE408, Placebo, AmBisome®)

Not yet recruiting

Primary Visceral Leishmaniasis

LXE408
+2 more

(no location specified)

Oct 20, 2022